

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**RECEIVED**  
**CENTRAL FAX CENTER**  
APR 23 2008

Appl. No. : 10/655,143  
INVENTOR : Beverly A. Rzigalinski et al.  
Filed : 09/04/2003  
Title : CERIUM OXIDE NANOPARTICLES AND USE IN ENHANCING CELL  
SURVIVABILITY  
TC/A.U. : 1617  
Examiner : Kendra D Carter  
Atty. Dkt. No. : UCF-375 Confirmation No.: 6531

Commissioner of Patents and Trademarks  
P.O. Box 1450  
Alexandria, VA 22313-1450

Via Facsimile to: (571) 273-8300

Honorable Commissioner:

I enclose the following papers: TOTAL PAGES 8 (including this cover sheet)

1. Amendment Response ( 7 pages)

Please enter the above correspondence.

Respectfully submitted,

Brian S. Steinberger  
Attorney at Law  
PTO Registration No. 36,423  
101 Brevard Avenue  
Cocoa, Florida 32922  
(321) 633-5080 Facsimile (321) 633-9322

## CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.6(d))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being sent by facsimile to the: Commissioner of Patents and Trademarks at fax phone (571) 273-8300.

4/23/08  
Date

Brian S. Steinberger  
(Name of Person Sending Attached Papers)

[Signature]  
(Signature of Person Sending Attached Papers)

Application Serial No.: 10/655,143  
Reply to Office Action of April 16, 2008

Atty. Dkt. No.  
UCF-375

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**RECEIVED  
CENTRAL FAX CENTER  
APR 23 2008**

Appl. No. : 10/655,143  
INVENTOR : Beverly A. Rzigalinski et al.  
Filed : 09/04/2003  
Title : CERIUM OXIDE NANOPARTICLES AND USE IN ENHANCING CELL  
SURVIVABILITY  
TC/A.U. : 1617  
Examiner : Kendra D Carter  
Atty. Dkt. No. : UCF-375 Confirmation No.: 6531

Commissioner of Patents and Trademarks  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT**

Sir:

In response to the Office Action mailed April 16, 2008, please amend the above-identified application as follows:

**Amendments to the Specification** begin on page 2 of this paper.

**Amendments to the Claims** are reflected in the listing of claims, which begin on page 3 of this paper.

**Remarks/Arguments** begin on page 5 of this paper.